Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...
An international, multidisciplinary team of leading neuro-oncology researchers and clinicians has released new ...
Conference call to discuss financial and operational results scheduled for ...
A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...
1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
Assessing when to initiate anticoagulation in atrial fibrillation is not improved by including gender, says the ESC in their ...
After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that ...
In a new NAE Perspective, Rory A. Cooper emphasizes that individuals with disabilities should be involved throughout the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback